Compare Prospect Capital Corporation (PSEC) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Prospect Capital Corporation vs Tango Therapeutics Inc. — how do they compare? Prospect Capital Corporation trades at $1.61 (market cap $848.77M), while Tango Therapeutics Inc. trades at $22.2 (market cap $3.74B). The key difference: Tango Therapeutics Inc. is far larger — about 4.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays a 26.42% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Tango Therapeutics Inc. for 0 Days on average.
| PSEC | TNGX | |
|---|---|---|
Market Cap | $848.77M | $3.74B |
Volume | 7,084,485 | 3,438,781 |
Sector | Financials | Health |
52-Week High | $3.05 | $32.90 |
52-Week Low | $1.60 | $7.50 |
Typical Hold Time | 78 Days | 0 Days |
Enterprise Value | $2.67B | $2.76B |
Dividend Yield | 26.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PSEC trades at $1.67, down 3.47% today, with bearish technical signals dominating. The stock shows mixed fundamentals with a low P/B ratio of 0.3x but negative revenue and net income in 2025. Recent earnings have consistently beaten expectations, though the company faces significant financial volatility with revenue swinging from $635M in 2022 to -$407M in 2025. Dividend distributions continue at $0.04 monthly, providing income appeal despite operational challenges.
The outlook remains cautious with analyst consensus leaning Hold (55%) amid financial instability. Key risks include persistent revenue volatility and negative cash flow. Upside potential exists from consistent earnings beats and deep valuation discounts, but investors should weigh income benefits against fundamental deterioration and bearish technical momentum.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Prospect Capital Corporation
Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.
Read more on PSEC →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
